Anumana develops advanced AI algorithms that analyze electrocardiogram (ECG) data to facilitate early diagnosis of cardiovascular conditions. The company focuses on enhancing cardiac care through innovative technology, providing healthcare professionals with tools to identify potential heart issues more effectively. Anumana's platform supports not only diagnostics but also aims to improve patient outcomes across the entire spectrum of cardiovascular care, including perioperative and acute settings. By employing machine learning techniques, Anumana seeks to refine screening processes, enabling clinicians to detect heart diseases and intervene promptly. This approach enhances healthcare delivery and promotes better management of cardiovascular health.
Rivos is a startup focused on developing high-performance RISC-V computing solutions aimed at enterprise applications. The company specializes in manufacturing computing chips designed to provide efficient and powerful server systems, particularly for large language models and data analytics. Rivos offers a comprehensive RISC-V-based server platform that includes optimized processors, a data parallel accelerator, and an open software stack. This integration allows developers to enhance the performance, security, and overall cost-effectiveness of their existing workloads. Through its innovative technology, Rivos seeks to meet the growing demands of modern computing environments.
ReCode Therapeutics is a biopharmaceutical company focused on developing precision medicines for pulmonary diseases, particularly targeting genetic conditions such as primary ciliary dyskinesia and cystic fibrosis. Founded in 2015 and based in Menlo Park, California, the company employs a unique non-viral lipid nanoparticle platform that facilitates the precise delivery of nucleic acid and protein payloads to specific organs and tissues, enhancing the effectiveness of genetic therapies. This selective organ targeting (SORT) technology allows for the administration of corrective or disease-modifying treatments beyond the liver, addressing the challenges faced by traditional gene therapy methods. By harnessing these innovative techniques, ReCode Therapeutics aims to provide new therapeutic options for patients suffering from rare and life-limiting respiratory diseases.
AltPep Corp is a biomedical startup that specializes in diagnosing and treating amyloid diseases, which are known for their challenging nature. The company operates a proprietary peptide-based platform designed to identify and neutralize toxic precursors associated with these diseases. This innovative approach includes diagnostic and therapeutic applications, particularly focused on the early detection of toxic oligomers in Alzheimer's disease through a soluble oligomer binding assay. By enabling healthcare institutions to detect and address amyloid diseases at an earlier stage, AltPep aims to enhance human health outcomes and improve treatment options for patients suffering from these conditions.
ElevateBio, LLC is a holding company based in Cambridge, Massachusetts, focused on the development of cell and gene-based therapies for treating cancer and viral infections. Founded in 2017 by Vikas Sinha, Mitchell Finer, and David Hallal, ElevateBio operates a portfolio of companies dedicated to creating life-changing medicines. The company collaborates with leading scientists and innovators to build this portfolio and has established a centralized facility that streamlines the transition from research and development to the commercialization of these therapies. This integrated approach enhances efficiency and accelerates the availability of medical products aimed at addressing severe diseases.
ACELYRIN is a biopharma company focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating the development and commercialization of promising drug candidates and by leveraging its expertise to rapidly advance these medicines to patients.
Monod Bio is a life sciences company based in Seattle, Washington, focused on developing innovative biosensors for detecting proteins, toxins, antibodies, and other analytes. Founded in 2021, the company has created a biosensor platform that integrates binding, transduction, and amplification processes in a single step, allowing for the rapid and sensitive detection of a diverse array of target molecules. By leveraging recent advancements in computational protein engineering, Monod Bio has designed highly modular bio-sensing nanoswitches that facilitate cost-effective analytical assays. This technology aims to enhance the capabilities of the healthcare industry in biotechnology and medicine.
ReCode Therapeutics is a biopharmaceutical company focused on developing precision medicines for pulmonary diseases, particularly targeting genetic conditions such as primary ciliary dyskinesia and cystic fibrosis. Founded in 2015 and based in Menlo Park, California, the company employs a unique non-viral lipid nanoparticle platform that facilitates the precise delivery of nucleic acid and protein payloads to specific organs and tissues, enhancing the effectiveness of genetic therapies. This selective organ targeting (SORT) technology allows for the administration of corrective or disease-modifying treatments beyond the liver, addressing the challenges faced by traditional gene therapy methods. By harnessing these innovative techniques, ReCode Therapeutics aims to provide new therapeutic options for patients suffering from rare and life-limiting respiratory diseases.
Talos Trading is a New York-based provider of institutional-grade technology infrastructure for the cryptocurrency market. Founded in 2018 by Anton Katz and Ethan Feldman, Talos offers a comprehensive trading platform that supports the entire trading lifecycle, from price discovery to clearing and settlement. The platform enables users to access spot, futures, and foreign exchange markets, facilitating seamless streaming of real-time prices and request for quote options. Additionally, it provides essential tools for portfolio accounting and market settlement, catering to the needs of various participants within the crypto ecosystem.
Koneksa Health Inc. is a healthcare data analytics company focused on enhancing clinical studies and disease research through the use of remotely generated patient data. The company's software, Koneksa Compare, facilitates the collection, visualization, and analysis of patient-generated data, incorporating emerging technologies such as bio-sensors, activity trackers, and mobile-based questionnaires. This platform allows pharmaceutical and biotech companies, as well as academic researchers, to make informed decisions and regulatory claims based on objective data. Koneksa also provides biometric devices that generate electronic clinical outcome assessments and offers a dashboard for monitoring patient engagement, which includes reminders for study subjects. Founded in 2013 and headquartered in New York, Koneksa has an additional office in London, United Kingdom.
Blockdaemon Inc. is a company that develops a blockchain node management platform, enabling businesses, enterprises, and developers to efficiently deploy and manage blockchain applications. The platform supports over 30 blockchain protocols, including Bitcoin, Ethereum, XRP, Tezos, and Polkadot, offering tools for exchanges, custodians, and financial institutions. Blockdaemon's solution is designed for flexibility, allowing users to switch between networks and chains easily, thus simplifying the configuration process. The company also provides valuable dev-ops guidance to support the blockchain developer ecosystem. Founded in 2013 and headquartered in Los Angeles, California, Blockdaemon has additional offices in New York and Ireland.
Solve Therapeutics is a biopharmaceutical company based in Belmont, California, founded in 2021. The company specializes in developing first-in-class antibody-drug conjugates and bispecific therapeutics. With a team of experienced professionals, Solve Therapeutics focuses on addressing unmet medical needs by creating innovative biopharmaceutical medicines aimed at improving patient outcomes.
Maze Therapeutics is a biotechnology company based in South San Francisco, California, focused on developing innovative medicines that leverage the effects of rare genetic variants to address unmet medical needs. Founded in 2017 and originally known as Modulus Therapeutics, the company utilizes its proprietary Compass platform to identify genetic variants linked to diseases and map them to the biological pathways that drive these conditions in specific patient populations. By integrating large-scale human genetics data and functional genomics with various drug discovery methods, Maze Therapeutics aims to reveal modifier genes that offer protective benefits. This approach enhances the understanding of target biology and informs the development of novel therapies, ultimately enabling pharmaceutical companies to create effective treatments.
Pramana, Inc. is a health technology company focused on transforming digital pathology for medical centers and pathology labs. It offers a comprehensive Digital Pathology as a Service (DPaaS) solution, which includes advanced whole slide imaging systems and a scalable software platform designed to enhance clinical workflows. By integrating the hardware capabilities from its predecessor, Spectral Insights, with nference's software expertise, Pramana provides a seamless service that enables pathologists to access high-quality images without operational challenges. Additionally, the company facilitates the use of AI-enabled decision support tools, enhancing the diagnostic process and ultimately improving patient care.
ACELYRIN is a biopharma company focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating the development and commercialization of promising drug candidates and by leveraging its expertise to rapidly advance these medicines to patients.
Bardavon Health Innovations, LLC specializes in developing and implementing healthcare technology and services focused on managing workers’ compensation cases. The company connects employers with essential tools to make informed decisions regarding employees in positions at risk of injury. Bardavon's technology facilitates efficient communication between therapy providers and referral sources, enhances reporting accuracy, and ensures consistent data tracking. Their solutions include targeted rehabilitation based on job analysis and clear communication of processes among various stakeholders. Bardavon's network provides real-time updates on patient status and supports the justification of therapy treatments for insurers and third-party administrators. Key offerings include bNOTES, bNOTES Connect, Telerehabilitation, Clinical Consulting, Job Analysis, Post-Offer Employment Testing, and XRTS Effort Assessment. Founded in 2013, Bardavon Health Innovations is headquartered in Overland Park, Kansas.
Blockdaemon Inc. is a company that develops a blockchain node management platform, enabling businesses, enterprises, and developers to efficiently deploy and manage blockchain applications. The platform supports over 30 blockchain protocols, including Bitcoin, Ethereum, XRP, Tezos, and Polkadot, offering tools for exchanges, custodians, and financial institutions. Blockdaemon's solution is designed for flexibility, allowing users to switch between networks and chains easily, thus simplifying the configuration process. The company also provides valuable dev-ops guidance to support the blockchain developer ecosystem. Founded in 2013 and headquartered in Los Angeles, California, Blockdaemon has additional offices in New York and Ireland.
GentiBio, Inc. is a biotherapeutics company focused on developing engineered regulatory T cells (EngTregs) aimed at treating autoimmune, alloimmune, autoinflammatory, and allergic diseases. Founded in 2020 and headquartered in Boston, Massachusetts, with additional locations in Israel and Seattle, GentiBio utilizes a proprietary platform that combines autologous and allogeneic EngTregs technologies. This innovative approach is designed to restore immune tolerance and address limitations present in current regulatory T-cell therapies. By targeting the underlying causes of diseases related to immune system dysfunction, GentiBio aims to provide effective therapeutic solutions for conditions that arise from immune system overshooting or malfunctioning. The company was co-founded by experts in Treg biology and synthetic immunology, positioning it at the forefront of this emerging field.
Emboline is a medical device company with a game-changing device for total embolic protection during percutaneous heart valve repair and replacement procedures and other cardiovascular procedures with embolic risks.
Anumana develops advanced AI algorithms that analyze electrocardiogram (ECG) data to facilitate early diagnosis of cardiovascular conditions. The company focuses on enhancing cardiac care through innovative technology, providing healthcare professionals with tools to identify potential heart issues more effectively. Anumana's platform supports not only diagnostics but also aims to improve patient outcomes across the entire spectrum of cardiovascular care, including perioperative and acute settings. By employing machine learning techniques, Anumana seeks to refine screening processes, enabling clinicians to detect heart diseases and intervene promptly. This approach enhances healthcare delivery and promotes better management of cardiovascular health.
Anumana develops advanced AI algorithms that analyze electrocardiogram (ECG) data to facilitate early diagnosis of cardiovascular conditions. The company focuses on enhancing cardiac care through innovative technology, providing healthcare professionals with tools to identify potential heart issues more effectively. Anumana's platform supports not only diagnostics but also aims to improve patient outcomes across the entire spectrum of cardiovascular care, including perioperative and acute settings. By employing machine learning techniques, Anumana seeks to refine screening processes, enabling clinicians to detect heart diseases and intervene promptly. This approach enhances healthcare delivery and promotes better management of cardiovascular health.
Aura Biosciences is a biotechnology company that focuses on the development of drugs by using tumor-targeted pseudovirions. The company is applying nanotechnology to help fight cancer in the well-studied area of chemotherapeutics and the emerging field of RNAi. By safely eliminating cancer locally, they can treat early and transform the lives of people with a wide range of cancers that are poorly managed today. The company's goal is to treat small ocular melanomas potentially long before the disease progresses and metastasizes to the liver, where it almost always is fatal. Aura Biosciences was founded in 2007 and is headquartered in Cambridge, Massachusetts.
ElevateBio, LLC is a holding company based in Cambridge, Massachusetts, focused on the development of cell and gene-based therapies for treating cancer and viral infections. Founded in 2017 by Vikas Sinha, Mitchell Finer, and David Hallal, ElevateBio operates a portfolio of companies dedicated to creating life-changing medicines. The company collaborates with leading scientists and innovators to build this portfolio and has established a centralized facility that streamlines the transition from research and development to the commercialization of these therapies. This integrated approach enhances efficiency and accelerates the availability of medical products aimed at addressing severe diseases.
AltPep Corp is a biomedical startup that specializes in diagnosing and treating amyloid diseases, which are known for their challenging nature. The company operates a proprietary peptide-based platform designed to identify and neutralize toxic precursors associated with these diseases. This innovative approach includes diagnostic and therapeutic applications, particularly focused on the early detection of toxic oligomers in Alzheimer's disease through a soluble oligomer binding assay. By enabling healthcare institutions to detect and address amyloid diseases at an earlier stage, AltPep aims to enhance human health outcomes and improve treatment options for patients suffering from these conditions.
nference, Inc. is a biotechnology company that offers an AI-based software platform designed to synthesize fragmented biomedical knowledge from various sources, including biomedical literature, molecular data, and real-world datasets. Founded in 2013 and headquartered in Cambridge, Massachusetts, with additional offices in Bengaluru, Toronto, and Rochester, nference provides advanced neural network models for the automated extraction of insights from scientific, clinical, regulatory, and commercial datasets. The company focuses on facilitating drug discovery, life cycle management, and precision medicine, enabling healthcare professionals and biopharmaceutical companies to develop personalized diagnostics and treatments for patients. By transforming electronic medical record data into actionable insights, nference addresses critical challenges in drug discovery and clinical research, enhancing patient care through comprehensive biological and clinical understanding.
Palleon Pharmaceuticals is a biotechnology company that develops therapeutics targeting glycan-mediated immune regulation for the treatment of cancer and inflammatory diseases. Founded in 2015 and based in Waltham, Massachusetts, the company specializes in creating glycoimmune checkpoint inhibitors, a novel class of drugs designed to enhance immune response against cancer. By integrating insights from global leaders in glycoscience and human immunology, Palleon aims to provide a broader array of combination therapies that not only address cancer but also combat resistance to traditional immuno-oncology treatments. Additionally, the company develops therapies for inflammatory diseases, including autoimmunity and fibrosis.
Encoded Therapeutics, Inc. is a biotechnology company that specializes in precision gene therapies aimed at treating a wide array of severe genetic disorders. Utilizing a unique platform, Encoded identifies sequences within the human genome that regulate gene expression through advanced screening and computational techniques. The company's therapy pipeline targets both genetic and acquired disorders across various disease pathways, including neurocircuitry, liver and metabolic disorders, neurodegeneration, and cardiovascular diseases. Founded in 2014 and based in South San Francisco, California, Encoded Therapeutics is focused on developing innovative solutions that enable medical practitioners to improve patient outcomes and enhance quality of life.
VelosBio, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing innovative antibody-drug conjugates (ADCs) to treat various forms of cancer, including hematological cancers and solid tumors. The company's primary area of research centers on targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1), a cell-surface protein found in numerous tumors but absent in normal tissues, which makes it a promising target for cancer therapy. VelosBio's lead product, VLS-101, is a ROR1-directed ADC that has shown positive preclinical results and aims to provide new treatment options for patients. Founded in 2017, VelosBio operates under the umbrella of Merck & Co., Inc. as of December 2020, focusing on developing targeted therapies that can be administered alone or in combination with other treatments across a wide range of cancer types.
nference, Inc. is a biotechnology company that offers an AI-based software platform designed to synthesize fragmented biomedical knowledge from various sources, including biomedical literature, molecular data, and real-world datasets. Founded in 2013 and headquartered in Cambridge, Massachusetts, with additional offices in Bengaluru, Toronto, and Rochester, nference provides advanced neural network models for the automated extraction of insights from scientific, clinical, regulatory, and commercial datasets. The company focuses on facilitating drug discovery, life cycle management, and precision medicine, enabling healthcare professionals and biopharmaceutical companies to develop personalized diagnostics and treatments for patients. By transforming electronic medical record data into actionable insights, nference addresses critical challenges in drug discovery and clinical research, enhancing patient care through comprehensive biological and clinical understanding.
Encoded Therapeutics, Inc. is a biotechnology company that specializes in precision gene therapies aimed at treating a wide array of severe genetic disorders. Utilizing a unique platform, Encoded identifies sequences within the human genome that regulate gene expression through advanced screening and computational techniques. The company's therapy pipeline targets both genetic and acquired disorders across various disease pathways, including neurocircuitry, liver and metabolic disorders, neurodegeneration, and cardiovascular diseases. Founded in 2014 and based in South San Francisco, California, Encoded Therapeutics is focused on developing innovative solutions that enable medical practitioners to improve patient outcomes and enhance quality of life.
nference, Inc. is a biotechnology company that offers an AI-based software platform designed to synthesize fragmented biomedical knowledge from various sources, including biomedical literature, molecular data, and real-world datasets. Founded in 2013 and headquartered in Cambridge, Massachusetts, with additional offices in Bengaluru, Toronto, and Rochester, nference provides advanced neural network models for the automated extraction of insights from scientific, clinical, regulatory, and commercial datasets. The company focuses on facilitating drug discovery, life cycle management, and precision medicine, enabling healthcare professionals and biopharmaceutical companies to develop personalized diagnostics and treatments for patients. By transforming electronic medical record data into actionable insights, nference addresses critical challenges in drug discovery and clinical research, enhancing patient care through comprehensive biological and clinical understanding.
Qrativ, Inc. is a biotechnology company based in Cambridge, Massachusetts, founded in 2017. It specializes in developing an AI-driven healthcare platform, known as Darwin.ai, which focuses on identifying new treatments for rare diseases with unmet medical needs. By leveraging machine learning and artificial intelligence, Qrativ's drug purposing platform facilitates the discovery and development of new uses for existing molecules, aiming to provide patients with access to treatments that are currently unavailable in the market. The company collaborates with biotechnology and pharmaceutical firms to enhance their research and development efforts in addressing these critical healthcare challenges.
EpiBiome, Inc. is a precision microbiome engineering company focused on developing therapies to combat infectious diseases in humans and agriculture without relying on small-molecule antibiotics. Founded in 2013 and based in South San Francisco, California, EpiBiome offers innovative phage therapy solutions that target specific strains within the microbiome, addressing issues such as antibiotic resistance and providing alternatives to traditional antibiotics. The company’s therapies are designed to treat conditions like mastitis in dairy cows and infections caused by Escherichia coli in humans. EpiBiome employs advanced sequencing and bioinformatic processes to identify pathogenic bacteria and microbiome alterations that may lead to disease, facilitating patient recovery and enhancing health outcomes. As of mid-2018, EpiBiome operates as a subsidiary of Locus Biosciences, Inc.
nference, Inc. is a biotechnology company that offers an AI-based software platform designed to synthesize fragmented biomedical knowledge from various sources, including biomedical literature, molecular data, and real-world datasets. Founded in 2013 and headquartered in Cambridge, Massachusetts, with additional offices in Bengaluru, Toronto, and Rochester, nference provides advanced neural network models for the automated extraction of insights from scientific, clinical, regulatory, and commercial datasets. The company focuses on facilitating drug discovery, life cycle management, and precision medicine, enabling healthcare professionals and biopharmaceutical companies to develop personalized diagnostics and treatments for patients. By transforming electronic medical record data into actionable insights, nference addresses critical challenges in drug discovery and clinical research, enhancing patient care through comprehensive biological and clinical understanding.
Adaptive Biotechnologies is a commercial-stage company focused on advancing immune-driven medicine by leveraging the adaptive immune system's biology to enhance disease diagnosis and treatment. Founded in 2009 and headquartered in Seattle, Washington, the company offers the clonoSEQ diagnostic test, which is authorized by the FDA for detecting and monitoring minimal residual disease in patients with specific blood cancers, including multiple myeloma and certain forms of leukemia. Additionally, Adaptive provides immunoSEQ services and kits for research purposes, aiding in the discovery of prognostic and diagnostic signals. The company is engaged in strategic collaborations with organizations such as Genentech and Microsoft to develop innovative therapies and diagnostic tools. Its offerings cater to life sciences research, clinical diagnostics, and drug discovery sectors.
Xero Limited is a New Zealand-based technology company that operates globally as a software as a service provider specializing in cloud-based accounting solutions. The company's flagship product, Xero, is designed for small and midsize enterprises, enabling users to manage cash flow, invoicing, payments, and reporting through an accessible online platform. Xero also offers a mobile application and various tools tailored for accountants and bookkeepers, including Xero HQ and Xero Practice Manager. Established in 2006 and headquartered in Wellington, Xero has rapidly gained market share in New Zealand and Australia, successfully challenging traditional accounting software providers. The company continues to expand its presence in other English-speaking markets, particularly in the United Kingdom, catering to a diverse range of industries such as retail, healthcare, hospitality, and e-commerce.
Xero Limited is a New Zealand-based technology company that operates globally as a software as a service provider specializing in cloud-based accounting solutions. The company's flagship product, Xero, is designed for small and midsize enterprises, enabling users to manage cash flow, invoicing, payments, and reporting through an accessible online platform. Xero also offers a mobile application and various tools tailored for accountants and bookkeepers, including Xero HQ and Xero Practice Manager. Established in 2006 and headquartered in Wellington, Xero has rapidly gained market share in New Zealand and Australia, successfully challenging traditional accounting software providers. The company continues to expand its presence in other English-speaking markets, particularly in the United Kingdom, catering to a diverse range of industries such as retail, healthcare, hospitality, and e-commerce.
Xero Limited is a New Zealand-based technology company that operates globally as a software as a service provider specializing in cloud-based accounting solutions. The company's flagship product, Xero, is designed for small and midsize enterprises, enabling users to manage cash flow, invoicing, payments, and reporting through an accessible online platform. Xero also offers a mobile application and various tools tailored for accountants and bookkeepers, including Xero HQ and Xero Practice Manager. Established in 2006 and headquartered in Wellington, Xero has rapidly gained market share in New Zealand and Australia, successfully challenging traditional accounting software providers. The company continues to expand its presence in other English-speaking markets, particularly in the United Kingdom, catering to a diverse range of industries such as retail, healthcare, hospitality, and e-commerce.
Tenor Networks, Inc. specializes in the development and manufacturing of optical switching systems and communications equipment. The company offers a range of products designed to enhance service intelligence for optical networks, including the TN250G, a Core MPLS Switch, and TEMPo, an element management platform. These products aim to improve the efficiency and management of optical communication systems, catering to the needs of modern network infrastructures.